Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
about
β-cell dedifferentiation in diabetes is important, but what is it?We can change the natural history of type 2 diabetes.Arginine is preferred to glucagon for stimulation testing of β-cell function.Q&A: insulin secretion and type 2 diabetes: why do β-cells fail?Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapyβ-Cell dysfunction in diabetes: a crisis of identity?Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes.Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes.Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.Association of lower body mass index with increased glycemic variability in patients with newly diagnosed type 2 diabetes: a cross-sectional study in China.Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
P2860
Q27011272-11F853E6-7472-490D-B840-DEF4062DAECBQ34219402-C3E6295C-92BA-45C9-BF76-6379E4F94116Q34356000-3950C391-8673-4536-9B49-0627E2B9F5CFQ35619020-2256C289-8377-4141-AACA-C15B5349B5FBQ38246691-E2225F56-C8D5-4F5A-B017-A18F1BBC0461Q38692092-16F89DD8-E589-4A39-92BB-BFAEF6C5E383Q38951175-954C2E2B-A567-4635-AE3C-02316A82D607Q39468025-07974FB0-A517-4A53-82B1-85DA2F523CD4Q41705110-2D1191A5-C2FC-4A9F-997A-CEE511E9B34EQ42511731-5CC17B62-C58E-4D9F-AA45-3BE5C6DF87A4Q42700690-71169DC8-E794-448A-8AF2-FBCCB71A7CA4Q48258498-D78F9C2F-3E76-4603-933F-E53FD3D5E63BQ58699251-9AB57466-D984-4162-BD19-6C5906AC99B0
P2860
Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Determinants of reversibility ...... ts with early type 2 diabetes.
@en
Determinants of reversibility ...... ts with early type 2 diabetes.
@nl
type
label
Determinants of reversibility ...... ts with early type 2 diabetes.
@en
Determinants of reversibility ...... ts with early type 2 diabetes.
@nl
prefLabel
Determinants of reversibility ...... ts with early type 2 diabetes.
@en
Determinants of reversibility ...... ts with early type 2 diabetes.
@nl
P2093
P2860
P1476
Determinants of reversibility ...... ts with early type 2 diabetes.
@en
P2093
Caroline Kaercher Kramer
Haysook Choi
Ravi Retnakaran
P2860
P304
P356
10.1152/AJPENDO.00447.2013
P577
2013-10-15T00:00:00Z